Tisotumab Vedotin – The Cancer Killer

1
Cancer is one of the most prevalent diseases that
patients suffer from across the globe. It could
be blood cancer, breast cancer, mouth cancer, or
any other kind of cancer. While there have been
a lot many experiments that have been conducted
over the years to help treat cancer patients,
none of them have proven to kill the cancer cells
completely from the body. But recently, a novel
cancer drug known as Tisotumab Vedotin has been
found which can destroy tumours from within the
body. This drug has shown promising results
across six different forms of cancer! These
included advanced drug-resistant cancers,
cervical cancers, lung cancers, bladder cancers,
and ovarian cancers. This is possible because the
drug releases a toxic substance to kill cancer
cells from within. With the success of this drug,
it has now been moved forward to the Phase-II
trials, where it will be further tested in a
range of additional cancer types like head,
neck, bowel, pancreatic, and squamous cell lung
cancers.
The Phase-I trial included 150 patients who had
various kinds of cancer, but had stopped
responding to standard treatments. The trial had
initially recruited only 27 patients to check
for the safety of the drug and establish its
right dose, and then expanded to 150 patients to
check if the drug was targeting the right
patients and goal, and to also check its
outcomes. The majority of patients tested in
this initial trial included those with advanced
stage cancer, and the bodies of whom had become
resistant to an average of three different types
of treatments. But, when the patients were
treated with Tisotumab Vedotin, 27 patients with
bladder cancer and cervical cancer, 14 patients
with ovarian cancer, 13 patients with lung
cancer and esophageal cancer, and 7 patients
with endometrial cancer responded positively to
it. And, these responses lasted for quite some
time, ranging between 5 to 10 months.
2
The positivity has been observed because of the
drug being made up of a toxic substance that is
attached to the tail end of an antibody, and
designed to seek out a receptor called tissue
factor that is present at high levels on the
surface of many cancer cells, and linked with
worse survival. This tissue factor draws the
drug inside the cancer cells, within which the
drug kills the cells. The mechanism of action of
this drug is completely different and unusual
it sneaks into the cancer cells and kills them
from within. With the experiments the drug has
gone through, it clearly shows that the drug has
the potential to treat a large number of
different types of cancer, especially those with
very poor survival rates. All these experiments
that are done are no piece of cake. It requires a
lot of caution, prudence, and judiciousness, and
most importantly a qualified education. One place
where such appropriate and legitimate education
and skill is offered to clinical research
aspirants by qualified professionals is Avigna
Clinical Research Institute, where flexible and
certified online clinical research courses are
offered that students can learn from anywhere
and anytime conveniently without compromising on
their current jobs and responsibilities.